Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Chelsea Therapeutics International, Ltd.v323335_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 10, 2012

 

CHELSEA THERAPEUTICS INTERNATIONAL, LTD.

 

(Exact name of registrant as specified in its charter)

 

Delaware   000-51462   20-3174202
(State or other jurisdiction of incorporation)   (Commission File
Number)
  (IRS Employer ID Number)

 

3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (704) 341-1516

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01. Other Events.

 

Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Chelsea Therapeutics International, Ltd. will present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference on September 10, 2012, and which is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No.   Description
     
99.1   PowerPoint presentation of September 10, 2012.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  CHELSEA THERAPEUTICS INTERNATIONAL, LTD. 
   
Date:  September 10, 2012 /s/ J. Nick Riehle
  J. Nick Riehle, Chief Financial Officer